Injecting OVV-01 and AK112 into tumors for advanced cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a new treatment that combines two drugs—OVV-01 (injected directly into tumors) and AK112 (given by vein)—for advanced solid cancers that have not responded to standard treatments. The goal is to see if this combination can shrink tumors and help patients live longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18 or older at enrollment
- Advanced solid tumor (like melanoma, lung, breast, colon, or liver cancer) confirmed by biopsy, and must have progressed after at least two prior standard treatments
- At least one tumor that can be seen on imaging and is large enough to inject (at least 10 mm for most tumors, 15 mm for lymph nodes)
- Good overall health status (able to perform light daily activities) with an expected survival of at least 12 weeks
- No active brain tumors or brain cancer spread (unless stable for 3+ months)
- No other active cancers in the past 5 years, and no HIV, hepatitis B/C, or syphilis infections with active disease
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new cancer treatment called OVV-01 that is injected directly into tumors or given through the vein. It's for patients with advanced solid cancers (like melanoma, lung, breast, or colon cancer) who have already tried at least two standard treatments without success.
This trial is testing a new drug called OTP-01 that targets two proteins (PD-1 and VEGFR2) to help your immune system fight cancer and stop tumors from growing. It is for people with advanced solid tumors that have not responded to or cannot have standard treatments.
This trial tests two experimental drugs, PE0116 and PE0105, for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the combination is safe and effective for cancers like kidney, head and neck, cervical, or ovarian cancer.
This trial tests an injection of your own immune cells (tumor-infiltrating lymphocytes) to see if they can fight advanced solid tumors like stomach or lung cancer. Doctors will remove one of your tumors, grow the immune cells from it, and then give them back to you.
This trial tests two injectable medications (OVV-01 and AK112) combined together to treat advanced soft tissue sarcoma—a cancer that has spread or cannot be surgically removed—in patients whose previous treatments have failed. The goal is to see if injecting these drugs directly into tumors can help shrink them and improve outcomes.
This trial tests a combination of two injections, OH2 and BS006, for people with advanced solid tumors that have not responded to standard treatments. The injections are given directly into the tumor, aiming to shrink or control the cancer.
Hear when a new Advanced Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.